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Abstract
Background: Indolent forms of mastocytosis account for more than 90% of all cases, but the types and type and severity of
symptoms and their impact on the quality of life have not been well studied. We therefore performed a case-control cohort
study to examine self-reported disability and impact of symptoms on the quality of life in patients with mastocytosis.
Methodology/Principal Findings: In 2004, 363 mastocytosis patients and 90 controls in France were asked to rate to their
overall disability (OPA score) and the severity of 38 individual symptoms. The latter was used to calculate a composite score
(AFIRMM score). Of the 363 respondents, 262 were part of an ongoing pathophysiological study so that the following data
were available: World Health Organization classification, standard measures of physical and psychological disability,
existence of the D816V KIT mutation, and serum tryptase level. The mean OPA and AFIRMM scores and the standard
measures of disability indicated that most mastocytosis patients suffer from disabilities due to the disease. Surprisingly, the
patient’s measurable and perceived disabilities did not differ according to disease classification or presence or absence of
the D816V KIT mutation or an elevated ($20 ng/mL) serum tryptase level. Also, 32 of the 38 AFIRMM symptoms were more
common in patients than controls, but there were not substantial differences according to disease classification, presence of
the D816V mutation, or the serum tryptase level.
Conclusions: On the basis of these results and for the purposes of treatment, we propose that mastocytosis be first
classified as aggressive or indolent and that indolent mastocytosis then be categorized according to the severity of patients’
perceived symptoms and their impact on the quality of life. In addition, it appears that mastocytosis patients suffer from
more symptoms and greater disability than previously thought, that mastocytosis may therefore be under-diagnosed, and
that the symptoms of the indolent forms of mastocytosis might be due more to systemic release of mediators than mast cell
burden.
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Introduction
Mastocytosis is a disease characterized by the excessive
accumulation of mast cells in at least one of several organs,
including the skin, bone marrow, lymph nodes, liver, spleen, and
gastrointestinal tract [1–3]. The true incidence of mastocytosis is
unknown, but the available evidence suggests that it is a rare
disease, with a prevalence of no more than 0.3 per 10,000, which
qualifies it as an orphan disease [4,5]. In aggressive forms of
mastocytosis, the accumulation of mast cells in organs and tissues
causes a loss of function and degeneration, which can decrease life
expectancy. Aggressive forms of mastocytosis are rare (,10% of all
cases) and require specific treatment aimed at reducing mast cell
infiltration and activity. Patients with indolent forms of mastocy-
tosis, however, do not have a decreased life expectancy or organ
damage, but they can suffer from a very wide variety of signs and
symptoms, including pruritus, flushing, syncope, hypotensive
shock, dizziness, abdominal pain, nausea, vomiting, diarrhea,
fatigue, memory loss, depression, tachycardia, palpitations,
breathing difficulties, fractures/osteoporosis, and pain in the
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muscles, joints, and bones [1–3]. These systemic manifestations
are believed to be due to the release of mast cell-derived mediators,
such as histamine, prostaglandins, heparin, neutral proteases, acid
hydrolases, chemokines, and cytokines.
Therefore, mastocytosis is now known to be a multidimensional
disease with a wide variety of signs and symptoms. This has
complicated its diagnosis, classification, and treatment. In 2001, to
help address this problem, the World Health Organization (WHO)
developed a consensus classification system for mastocytosis [2].
This system separates mastocytosis into cutaneous mastocytosis
(CM) and five main subtypes of systemic mastocytosis (SM),
including indolent SM, SM with an associated hematologic clonal,
non-mast cell lineage disease, aggressive SM, smoldering SM, and
mast cell leukemia. CM is diagnosed by the presence of skin lesions
and the absence of definitive systemic involvement by mast cells.
In the majority of cases, a diagnosis of SM is established by
evidence of mast cell infiltration in the bone marrow or, less
frequently, the liver, spleen or gastrointestinal tract. Minor criteria
for a diagnosis of SM can include abnormal mast cell
morphologies in the bone marrow and other extracutaneous
organs, mutation of the tyrosine kinase KIT at codon 816,
expression of CD2 and/or CD25 by bone marrow mast cells, and
a serum tryptase level .20 ng/mL. CM is most common in
children before puberty, most often presents as a rash or urticaria
pigmentosa, and often resolves spontaneously. In adults, however,
CM frequently progresses to SM. In contrast to CM, SM has a
peak onset in adults, tends to be more aggressive, and can involve
the skin as well as internal organs and bone marrow. Indolent SM
accounts for 90% of the cases of SM and generally appears to have
a good prognosis, although a wide variety of mediator-related
symptoms are common, and these can be disabling or even life-
threatening as in the case of hypotensive shock [3].
In the last 15 years, activating mutations have been found in
codon 816 of the tyrosine kinase KIT in children and adults with
mastocytosis [6]. In particular, the D816V mutation has been
found in most (.80%) of patients with SM and therefore has been
thought to promote the development of systemic and persistent
disease. Furthermore, a recent study showed that expression of
KIT with the D816V mutation causes mastocytosis in transgenic
mice [7]. For this reason, inhibitors of the KIT tyrosine kinase are
being developed for the treatment of mastocytosis [1].
Since 2001, to help understand the pathophysiology of
mastocytosis and improve its treatment, AFIRMM (Association
Franc¸aise pour les Initiatives et la Recherche sur le Mastocyte et
les Mastocytoses; http://www.afirmm.com/) has collected data on
mastocytosis patients in France. To help physicians in the selection
of appropriate treatments for mastocytosis, we performed a case-
control study within the AFIRMM network to assess the patients’
perception of symptoms and the impact on their quality of life. On
the basis of this information, we developed and validated a
composite score that measures mastocytosis patients’ perception of
disability (AFIRMM score). Using this score and an overall rating
of self-perceived disability (OPA score), we examined the
relationship between disability and the disease classification, the
presence of the D816V KIT mutation, and the serum tryptase
level. The AFIRMM score also allowed us to identify the
symptoms that most contributed to the patients’ perception of
disability.
Methods
The AFIRMM network
The AFIRMM network (http://www.afirmm.com/) was creat-
ed in France in 1999 to collect data on patients suffering from
mastocytosis, inform health care professionals and patients about
mast cell disorders, support research to better understand mast cell
disorders and thereby develop efficient symptomatic or curative
treatments. The AFIRMM network currently includes more than
68 hospitals and clinical centers in France and Switzerland
(principal investigators O.H. and O.L., Centre de re´fe´rence de
mastocytose, Hoˆpital Necker, Paris, France). Between 1999 and
2004, 1297 adult mastocytosis patients were identified in France
by AFIRMM.
Study design and objectives
A case-control study was initiated in September 2004 by
AFIRMM to examine patients’ disability due to mastocytosis. The
objectives of the current cohort study were to (i) evaluate the
patients’ perception of disability, (ii) establish and validate a
composite score for disability, (iii) determine the most important
symptoms causing the patients’ perception of disability, and (iv)
correlate disability with mastocytosis classification and presence of
the D816V KIT mutation and an elevated level of serum tryptase.
Patients and data collection
For the mastocytosis patient cohort, all adult ($18 years) patients
suffering mastocytosis identified by AFIRMM between 1999 and
2004 were eligible. In September 2004, AFIRMM sent question-
naires to 703 of the identified adult patients. The patients were asked
to respond to (i) a unidimensional questionnaire on their overall
perception of disability (overall patient assessment [OPA] question-
naire) and (ii) a multidimensional questionnaire containing 38 items
on the patient’s perception of disability from individual symptoms
(AFIRMM questionnaire). Of the 703 patients that were sent
questionnaires, 363 provided responses. At the same time or at a
later date, the patients were also administered questionnaires to
assess seven measurable parameters of disability (see ‘‘Measurable
parameters of disability’’ below). All questionnaires were returned to
and processed at the Service d’He´matologie, Hoˆpital Necker (Paris,
France). The case-control cohort included 90 members of the
medical staff or their family members that were unaffected by and
with no family member affected by mastocytosis. Data from
questionnaires were collected according to French privacy laws,
and all parts of the study were approved by the Ethics Committee of
the Hoˆpital Necker, Paris, France.
Of the 363 patients that responded, 262 were part of an ongoing
pathophysiological study started in November 2003 by AFIRMM.
The patients selected and enrolled in the pathophysiological study
included (i) patients suffering CM as documented by a skin biopsy
and without mast cells in other tissues and (ii) patients suffering from
SM as documented by mast cell infiltration in a bone marrow and/
or another internal organ (i.e., liver or gastrointestinal tract) with or
without skin involvement. In addition, all patients had to be affiliated
with a social security regimen or covered by insurance. The patients
in the pathophysiological study were recruited by investigators
following a consultation where the investigator verbally informed the
patients about the aims and conditions of the study. The patient
received a patient information sheet, and written informed consent
was obtained prior to the initiation of all study procedures. For these
262 patients, the following were collected or performed during a
medical visit: demographics, information related to the diagnosis of
mastocytosis, previous data on organ involvement and KIT
characterization, WHO classification, physical examination (weight
and vital signs), clinical examination (cutaneous and systemic
symptoms), biological examination (hematology, biochemistry
laboratory tests, and serum tryptase level), radiological examination,
blood samples, skin biopsy, and bone marrow aspirate and/or
biopsy. For these patients, a confirmation of diagnosis was given by a
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centralized review of all previous clinical and histopathological
assessments. All procedures in the pathophysiological study were
conducted according to guidelines for Good Clinical Practice [8].
OPA Score
The OPA score was determined from a unidimensional
questionnaire, where the patients were asked, ‘‘How do you assess
your disability in general (pain, general health status, impact on
your life)? Grade 0, no disability; grade 1, light disability; grade 2,
moderate disability; grade 3, severe disability; grade 4, intolerable
disability.’’
AFIRMM Score
A mutidimensional questionnaire (see Supporting Information)
was designed by AFIRMM to collect information on patients’
perception of the severity of their symptoms and their impact on
the quality of life. The questionnaire was designed on the basis of
patient interviews between 1999 and 2004 to include the most
commonly reported symptoms. There were a total of 38 specific
symptoms in 12 categories (skin, allergy/flush/shock, gastrointes-
tinal tract, rheumatology, asthenia, neurology/psychiatry, respi-
ratory, urology, infection, hemorrhoidal inflammation, libido, and
sweat). Each disability was assigned a grade between 0 and 4 (0,
none; 1, light; 2, moderate; 3, severe; 4, intolerable). In addition,
each disability grade was assigned a weighting of 1 to 5 to reflect
the impact of the symptom’s severity on the quality of life. The
AFIRMM score was then calculated as follows:
AFIRMM Score~
X38
n~1
Graden|Weightn,
where n is the symptom number, Grade is the self-assessed severity
of the symptom (0–4), and Weight=Grade+1. The resulting
AFIRMM score can range from a minimum of 0 (no disability)
to a maximum of 760 (most severe disability).
Measurable parameters of disability
AFIRMM selected seven measurable parameters to confirm
disability in mastocytosis. This included four quantifiable disabil-
ities: existence of life-threatening anaphylactoid episodes, number
of flushing episodes per week, number of stools per day, and
number of micturitions per day. In addition, three scores used to
measure disability in other pathologies were assessed: a pruritus
score (see Supporting Information), the Hamilton score for
depression [9], and the QLQ-C30 quality of life score [10]. For
these measures, the following were considered as indicating a
disability: the existence of recurrent life-threatening anaphylactoid
episodes, $7 episodes of flushing per week, $4 stools per day
(diarrhea), $8 micturitions per day (pollakiuria), pruritus score
$6, Hamilton score $10 (depression), QLQ-C30 score $60.
Detection of D816V KIT mutation
For patients with CM, biopsies were collected from skin lesions,
and for patients with SM, bone marrow aspirates were collected
from the sternum or iliac crest. Bone marrow samples (3 mL) were
collected in an EDTA tube (Becton Dickinson), and skin samples
consisted of two to three punch biopsies of 3 to 4 mm from a
cutaneous lesion collected in 1 mL of RNAlater (Qiagen). All
biopsy samples were sent to Fabienne Palmerini, Institut Paoli
Calmettes (Marseille, France) at room temperature. Samples
arrived within 36 to 60 h. Immediately after reception, skin
samples were frozen at 280uC, and prior to RNA extraction, they
were homogenized using a Polytron T25 Ultra-turrax (Fisher
Bioblock Scientific) in RLT buffer at room temperature. Marrow
samples were mixed with NH4Cl lysis solution (8.3 g/L NH4Cl,
0.81 g/L NaHCO3, and 0.37 g/L EDTA) and incubated for
10 min at 4uC to lyse red blood cells. The marrow cells were then
sedimented by centrifugation at 1806 g for 10 min, washed with
phosphate-buffered saline, pH 7.4 (Gibco), resuspended in RLT
buffer (Qiagen), and stored at 280uC for later RNA extraction.
Total RNA was extracted from thawed samples using an
RNeasy Mini Kit (Qiagen). Complementary DNA (cDNA) was
synthesized in a total volume of 50 ml containing 200 ng of total
RNA, random hexamers, and oligo dT using the StrataScript first-
strand synthesis system (Stratagene) according to the manufactur-
er’s instructions. Next, 2.5 ml of cDNA was amplified by PCR
using HotStartTaqTM DNA polymerase (Qiagen) and primers 59-
GGATGACGAGTTGGCCCTAGA-39 and 59-GTAGAAACT-
TAGATCGACCGGCA-39. Amplification was carried out for 40
cycles at 94uC for 30 s, 57uC for 30 s, and 72uC for 45 s. PCR
products were purified with the Geneclean III kit (Qbiogene) and
directly sequenced using a BigDye terminator kit v1.1 (Applied
Biosystems) with primers 59-TACCAGGTGGCAAAGGG-
CATG-39 and 59-CGACCGGCATTCCAGGATAG-39 on an
ABI Prism 3130 sequencer (Applied Biosystems). The entire
coding region for KIT was sequenced, and the obtained sequences
were analyzed with Seqscape software (Applied Biosystems).
The presence of the D816V mutation was also confirmed by
restriction digestion analysis using BsmA1 and Ple1, which detect
the wild-type and mutated form of KIT, respectively. The cDNA
was amplified by PCR as described above but using fluorescently
labeled primers. The size of restriction digest fragments (201 bp
for the BsmA1 fragment and 179 and 187 for the Ple1 fragment)
were then directly determined on a 16-capillary sequencer (ABI
Prism 3130) by comparison with Genescan rox 500 markers
(Applied Biosystems) using GeneMapper software (Applied
Biosystems).
Measurement of serum tryptase
The level of total tryptase (a-protryptase+b-tryptase) in serum
samples was determined using a fluorescence enzyme-linked
immunoassay (Unicap; Pharmacia) [11]. The detection limit of
this assay is 1 ng/mL, and in healthy controls, serum tryptase
levels range between,1 and 15 ng/mL, with a median of,5 ng/
mL [12].
Statistical analyses
Statistical analyses were performed using SAS version 9.1 (SAS
Institute) and Excel (Microsoft Corp.). Quantitative variables were
summarized using the following descriptive statistics: number of
observed and missing data, mean, standard deviation, median,
minimum and maximum. Absolute and relative frequency
distributions were provided for qualitative variables. Qualitative
variables were compared using a Chi-square test or Fisher exact
test if at least one of the expected counts was less than five.
Normally distributed quantitative variables were compared using
Student’s t-test. Distributed quantitative variables that did not
have a normal distribution were compared using Wilcoxon’s rank
sum test. P,0.05 was considered to indicate a statistically
significant difference.
Results
Patient characteristics and data collected
During visits by mastocytosis patients between 1999 and 2004,
we noticed that they tend to suffer from a very wide variety of
common symptoms and that they often feel disabled by these
Disability in Mastocytosis
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symptoms. To gain a clearer picture of overall disability in
mastocytosis and the type and severity of symptoms causing
disability, we developed two questionnaires. The first was a
unidimensional questionnaire asking the patients about their
overall perception of disability (OPA questionnaire), and the
second was a multidimensional questionnaire asking the patients
about their perception of the severity of 38 symptoms in 12
categories (AFIRMM questionnaire; Table S1). In September
2004, we sent the questionnaires to 703 adult mastocytosis patients
that had been identified by AFIRMM in France between 1999
and 2004. Responses to both questionnaires were obtained from
363 patients, 262 of whom were part of an ongoing pathophys-
iological study by AFIRMM. In addition, the questionnaires were
administered to 90 control healthy subjects with no family
members suffering from mastocytosis. The 363 patients included
individuals with CM and both indolent and aggressive forms of
SM, but none of the patients had mast cell leukemia (data not
shown). Of the 262 patients in the pathophysiological study, 62
had their mastocytosis further validated by a central review of
pathological samples and clinical data at Hoˆpital Necker (Figure 1).
OPA Score
First, we compared the OPA scores between the patient and
control cohorts (Table S2). The OPA score was based on patients’
response to a single question: ‘‘How do you assess your disability in
general (pain, overall health status, impact on your life)?’’ Of the
363 patients in the patient cohort, 254 (70%) declared that they
suffered from a disability, including 62 (17%) who said it was
severe or intolerable, whereas only 8 of 90 (9%) of the control
patients said they had a disability (P,0.001 by Chi square test).
Also, in contrast to the patients, none of the controls reported
having a severe or intolerable disability.
We further examined the OPA score in the 262 patients in the
pathophysiological study and the 62 patients whose mastocytosis
was confirmed by a central review of pathological and clinical data
at Hoˆpital Necker. Again, we found a significant difference in the
fraction reporting a disability between the patients and controls.
Thus, regardless of the level of validation, mastocytosis patients
feel disabled by their disease.
We next examined whether the OPA score was different
between patients with CM and SM (Table 1). Of the 262 patients
for whom pathophysiological data was available, the WHO
classification was known for 115. Of these, 33 (29%) were
diagnosed with CM and the remaining 82 (71%) with SM. For
patients diagnosed with CM, 64% (21/33) declared that they
suffered from a disability, including 15% (5/33) who said that it
was severe or intolerable, and of those with SM, 82% (67/82)
reported having a disability and 28% (23/82) declared that it was
severe or intolerable. The proportion declaring a disability was
slightly different (P=0.0386 by Chi square test) between patients
with CM and SM; however, the difference was not significant
when the analysis was limited to patients whose mastocytosis was
further validated by a central review of all pathological and clinical
data. These results indicate that CM and SM patients feel equally
disabled by their disease.
Because the KIT D816V mutation is suggested to correlate with
the occurrence of SM in adult patients and to contribute to its
progression [1,13], we next examined whether it correlates with
the OPA score (Table 1). The KIT status was known for 234
patients and the serum tryptase level for 140 of the patients. There
was no difference in the OPA score according to the presence of
the D816V KIT mutation for all patients whose classification was
known or for patients whose mastocytosis was confirmed by a
central review of pathological and clinical data. Collectively, these
results indicate that patients’ overall perception of disability is
unrelated to the presence of the D816V mutation.
We also examined the correlation between the OPA score and
the total serum tryptase level because a level $20 ng/mL is used
as a criterion for a diagnosis SM [2,14,15]. In addition, recent
studies show that the serum tryptase level positively correlates with
Figure 1. Control and patient groups in this study. A total of 363 patients and 90 controls answered AFIRMM and OPA questionnaires. Of the
363 patients, 262 were part of an ongoing pathophysiological study. Of these 262, 62 had their mastocytosis further validated by a careful centralized
review of pathological samples and clinical data at Hoˆpital Necker.
doi:10.1371/journal.pone.0002266.g001
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the severity category of SM [16,17]. As shown in Table 1, there
was no significant difference between the OPA score according to
the presence of an elevated ($20 ng/mL) serum tryptase level.
This was also found when the analysis was limited to patients
whose mastocytosis was validated by a central review of
pathological and clinical data. These findings indicate that the
patients’ overall perception of disability is unrelated to whether
they have an elevated serum tryptase level.
AFIRMM score
To allow analysis of the severity of the individual symptoms and
their contribution to the patients’ perception of disability in
mastocytosis, we designed a questionnaire that assesses the severity
or self-perceived severity of 38 distinct symptoms in 12 different
categories. Each symptom was given a grade from 0 to 4, and each
grade was assigned a weight from 1 to 5 to reflect the impact of
each level of disability on the quality of life. This information was
used to calculate a composite score (AFIRMM score) that ranged
from 0 to 760 (from least to most severe).
As shown in Table 2, the mean AFIRMM score was significantly
higher for the patient cohort than for the control cohort (mean6-
standard deviation, 117678 [n=363] vs. 29627 [n=90];
P,0.0001). This result was also found when the analysis was limited
to the 262 patients who were part of the pathophysiological study
and to the subsets of patients whose mastocytosis was validated by a
central review of pathological and clinical data.
We found a slight difference in the AFIRMM score between
patients with CM and SM (mean6standard deviation, 103675
[n= 33] vs. 135682 [n= 90]; P=0.0225), but the difference was
not significant when the analysis was limited to patients whose
mastocytosis was validated by a central review of pathological and
clinical data (Table 2). There was also not a significant difference
between the AFIRMM score according to the presence or absence
of the KIT D816V mutation or a serum tryptase level .20 ng/
mL, regardless of the subgroup of patients analyzed. These results
agree with the findings from the OPA score that mastocytosis
patients feel disabled by their symptoms regardless of whether they
have CM or SM, that the overall extent of disability does not differ
significantly between these two main types of mastocytosis, and
that overall disability is unrelated to the presence of the presence of
the D816V mutation or an elevated serum tryptase level. Thus,
the AFIRMM score appears to reflect the patients’ overall
perception of disability from mastocytosis.
We next examined the results on a symptom-by-symptom
basis. We found that for the vast majority (32/38) of symptoms,
there was a statistically significant difference in the proportion of
patients and controls reporting some disability (grades 1–4)
(Table 3). According to the score (Grade6Weight), the 10
symptoms most contributing to the patients’ perception of
disability were (in decreasing order) psychological impact of
cutaneous problems, asthenia (fatigue), pruritus, food allergy/
intolerance, erythemateous crisis, muscle and joint pain/
Table 1. OPA scores.
Variable Group n Perceived Handicap
Population None Light Moderate Severe Intolerable P-value
All cases
Controls 90 82 (91%) 5 (6%) 3 (3%) 0 (0%) 0 (0%)
All patients 363 109 (30%) 107 (29%) 85 (23%) 59 (16%) 3 (1%) ,0.0001a
Patients in pathophysiological study 262 68 (26%) 75 (29%) 68 (26%) 49 (19%) 2 (1%) ,0.0001a
Patients confirmed by central review 62 8 (13%) 21 (34%) 16 (26%) 16 (26%) 1 (2%) ,0.0001a
Clinical form
Patients in pathophysiological study CM 33 12 (36%) 7 (21%) 9 (27%) 5 (15%) 0 (0%) 0.0386b
SM 82 15 (18%) 28 (34%) 16 (20%) 22 (27%) 1 (1%)
Patients confirmed by central review CM 13 2 (15%) 3 (23%) 6 (46%) 2 (15%) 0 (0%) 0.61c
SM 44 4 (9%) 15 (34%) 10 (23%) 14 (32%) 1 (2%)
KIT status
Patients in pathophysiological study D816V 72 17 (24%) 19 (26%) 19 (26%) 16 (22%) 1 (1%) 0.64d
No D816V 162 43 (27%) 52 (32%) 43 (27%) 23 (14%) 1 (1%)
Patients confirmed by central review D816V 16 2 (13%) 3 (19%) 6 (38%) 5 (31%) 0 (0%) 1.00e
No D816V 40 6 (15%) 16 (40%) 10 (25%) 7 (18%) 1 (3%)
Serum tryptase
Patients in pathophysiological study ,20 ng/mL 53 12 (23%) 16 (30%) 13 (25%) 11 (21%) 1 (2%) 0.52f
$20 ng/mL 87 24 (28%) 24 (28%) 19 (22%) 20 (23%) 0 (0%)
Patients confirmed by central review ,20 ng/mL 20 2 (10%) 7 (35%) 6 (30%) 4 (20%) 1 (5%) 0.70g
$20 ng/mL 34 6 (18%) 12 (35%) 7 (21%) 9 (26%) 0 (0%)
aP-value calculated by Chi-square test for patients reporting a handicap vs. control.
bP-value calculated between CM and SM by Chi-square test.
cP-value calculated between CM and SM by Fisher’s exact test.
dP-value calculated between presence and absence of D816V KIT mutation by Chi-square test.
eP-value calculated between presence and absence of D816V KIT mutation by Fisher’s exact test.
fP-value calculated between serum tryptase #20 and .20 ng/mL by Chi-square test.
gP-value calculated between serum tryptase #20 and .20 ng/mL by Fisher exact test. Statistically significant differences (,0.05) are shown in italics
doi:10.1371/journal.pone.0002266.t001
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cramps, pollakiuria, drug allergy, aerophagia/eruction, and
dyspnea/bronchoreactivity. When the analysis was limited to
patients whose mastocytosis was validated by a central review,
there was some variability in whether certain symptoms (i.e.,
aerophagia/eruction, ocular discomfort, erectile function/abil-
ity to make love, and dysuria) were statistically significant or not
(data not shown); however, except for dysuria, when only severe
or intolerable disabilities (grades 3 or 4) were considered, all of
these were found to be significantly more common in patients
than in controls (Table 3), suggesting that they represent
disabling symptoms of mastocytosis.
For the vast majority of individual symptoms, perceived
disability did not differ between CM and SM patients (Table 4).
Reduced erections or ability to make love was the only exception:
a disability was reported by more SM than CM patients (31% vs.
3%; P=0.0013), and a substantial portion (15%) of SM patients
but none of the CM patients (P=0.0176) reported this symptom as
severe or intolerable. Also, slightly more SM patients reported
disability from pseudo-occlusive syndrome (57% vs. 33%;
P=0.0200) and muscle/joint pain and cramps (88% vs. 70%;
P=0.0205), although the frequencies were not significantly
different when only severe or intolerable disabilities (grades 3 or
4) were considered.
Comparison of the extent of disability from the individual
symptoms according to the presence or absence of the D816V
mutation also revealed few substantial differences (Table 5).
Three of the 38 symptoms (erythemateous crisis, psychological
impact, and pseudo-occlusive syndrome) were more common in
those with the D816V mutation, and five symptoms (olfactive
intolerance, gastric pain, mobility, ocular disorders, and
stomatitis) were more common in those without the mutation.
Of these, only the psychological impact of cutaneous problems
was significantly different (more common in those with the
D816V mutation) when only severe or intolerable disabilities
were considered.
The extent of disability for the individual symptoms did not
appear to differ according to the presence or absence of an
elevated (.20 ng/mL) serum tryptase level (Table 6). Ocular
discomfort was somewhat more common in patients with a serum
tryptase level #20 ng/mL, but this difference was not observed
when only severe or intolerable disabilities were considered.
Standard measures of disability
At the same time or subsequent to completing the OPA and
AFIRMM questionnaires, the patients were asked to respond to
questionnaires to assess standard measures of disability. This
included four quantifiable measures of disability (existence of life-
threatening anaphalactoid episodes, number of flushes per week,
number of stools per day, and number of micturitions per day) and
three scores that have been used to assess disability in other
diseases, namely, pruritus score, Hamilton score for depression [9],
and QLQ-C30 score, which was designed to measure the quality
of life in oncology patients [10]. Patients were considered to have a
disability when they had recurrent life-threatening anaphylactoid
episodes (19%), $7 episodes of flushing per week (66%), $4 stools
per day (12%),$8 micturitions per day (32%), a pruritus score $6
Table 2. AFIRMM scores.
Variable Group n Mean6SD Median Min–Max P-value
Population
All cases
Controls 90 29627 21 0–150 –
All patients 363 117684 104 ,0.0001a
Patients in pathophysiological study 262 124.8679.9 111 6.0–410.0 ,0.0001a
Patients confirmed by central review 62 144.5683.3 133 22.0–410.0 ,0.0001a
Clinical form
Patients in pathophysiological study CM 33 103675 84 20–408 0.0225b
SM 82 135682 124 6–410
Patients confirmed by central review CM 13 145.7695.0 128 46.0–408.0 0.54b
SM 44 152.9679.0 144 50.0–410.0
KIT status
Patients in pathophysiological study D816V 72 129679 119 6–358 0.29c
No D816V 162 119679 104 6–410
Patients confirmed by central review D816V 16 136.0665.2 130 28.0–240.0 0.96c
No D816V 40 145.5690.4 129 22.0–410.0
Serum tryptase
Patients in pathophysiological study ,20 ng/mL 53 117675 116 26–410 0.86d
$20 ng/mL 87 121682 102 6–408
Patients confirmed by central review ,20 ng/mL 20 139.6691.1 121 28.0–410.0 0.99d
$20 ng/mL 34 137.6683.5 128 22.0–408.0
aP-value for patient group vs. control cohort by Wilcoxson test.
bP-value for CM vs. SM by Wilcoxson test.
cP-values for D816V vs. no D816V by Wilcoxson test.
dP-value for serum tryptase #20 ng/mL vs. .20 ng/mL by Wilcoxson test. Statistically significant differences (,0.05) are shown in italics.
doi:10.1371/journal.pone.0002266.t002
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(77%), a Hamilton rating score $10 (75%), or a QLQ-C30 score
$60 (32%) (Table 7). According to these scores, 61% of all
responding mastocytosis patients presented at least one disability.
Furthermore, there were no significant differences in these seven
parameters of disability by clinical form (CM vs. SM; Table 8), the
presence or absence of the KIT D818V mutation (Table 9), or the
presence or absence of a serum tryptase level $20 ng/mL
(Table 10).
Table 3. Disability by symptom: patients vs. controls.
Symptom Ranka Controls Patients P-value
b
n
Any
disabilityc
Severe or
intolerable
disabilityd n
Any
disabilityc
Severe or
intolerable
disabilityd
Any
disabilityc
Severe or
intolerable
disabilityd
Psychological impact 1 90 9 (10%) 1 (1%) 363 261 (72%) 120 (33%) ,0.0001 ,0.0001
Asthenia 2 90 34 (38%) 3 (3%) 362 296 (82%) 102 (28%) ,0.0001 ,0.0001
Pruritus 3 90 25 (28%) 3 (3%) 363 299 (82%) 82 (23%) ,0.0001 ,0.0001
Food allergy/intolerance 4 90 9 (10%) 0 (0%) 363 222 (61%) 97 (27%) ,0.0001 ,0.0001
Erythemateous crisis 5 90 17 (19%) 1 (1%) 363 293 (81%) 69 (19%) ,0.0001 ,0.0001
Muscle and joint pain, cramps 6 90 36 (40%) 3 (3%) 363 276 (76%) 71 (20%) ,0.0001 0.0002
Pollakiuria 7 90 58 (64%) 6 (7%) 362 263 (73%) 64 (18%) 0.12 0.0098
Drug allergy 8 90 16 (18%) 0 (0%) 363 205 (56%) 70 (19%) ,0.0001 ,0.0001
Aerophagia/eructation 9 90 43 (48%) 1 (1%) 363 229 (63%) 62 (17%) 0.0080 ,0.0001
Dyspnea/bronchoreactivity 10 90 15 (17%) 3 (3%) 362 154 (43%) 94 (26%) ,0.0001 ,0.0001
Headache 11 90 34 (38%) 4 (4%) 362 250 (69%) 48 (13%) ,0.0001 0.0190
Bone pain 12 90 16 (18%) 0 (0%) 363 196 (54%) 65 (18%) ,0.0001 ,0.0001
Reduced sexual relations 13 90 11 (12%) 4 (4%) 362 132 (36%) 65 (18%) ,0.0001 0.0014
Epigastric pain 14 90 35 (39%) 2 (2%) 362 249 (69%) 40 (11%) ,0.0001 0.0100
Ocular discomfort 15 90 43 (48%) 1 (1%) 363 219 (60%) 55 (15%) 0.0309 0.0003
Memory loss 16 90 32 (36%) 0 (0%) 362 240 (66%) 34 (9%) ,0.0001 0.0025
Tinnitus 17 90 29 (32%) 1 (1%) 363 166 (46%) 47 (13%) 0.0205 0.0011
Pseudo-occlusive syndrome 18 90 20 (22%) 0 (0%) 363 199 (55%) 36 (10%) ,0.0001 0.0018
Infections (bronchitis, rhinitis,
conjunctivitis)
19 90 25 (28%) 2 (2%) 363 182 (50%) 38 (10%) 0.0001 0.0136
Olfactive intolerance 20 90 33 (37%) 1 (1%) 363 188 (52%) 39 (11%) 0.0102 0.0039
Social interaction 21 90 9 (10%) 0 (0%) 362 200 (55%) 26 (7%) ,0.0001 0.0088
Depression 22 90 19 (21%) 0 (0%) 362 205 (57%) 22 (6%) ,0.0001 0.0114e
Mobility 23 90 6 (7%) 0 (0%) 363 153 (42%) 35 (10%) ,0.0001 0.0022
Anaphylactic shock 24 90 12 (13%) 0 (0%) 363 160 (44%) 30 (8%) ,0.0001 0.0048
Sweating 25 90 19 (21%) 2 (2%) 363 169 (47%) 30 (8%) ,0.0001 0.0452
Stomatitis 26 90 28 (31%) 1 (1%) 363 145 (40%) 34 (9%) 0.12 0.0086
Flush 27 90 9 (10%) 0 (0%) 363 190 (52%) 23 (6%) ,0.0001 0.0123e
Performance status 28 90 11 (12%) 1 (1%) 362 187 (52%) 25 (7%) ,0.0001 0.0346
Hemorrhoids 29 90 19 (21%) 1 (1%) 363 156 (43%) 23 (6%) 0.0001 0.06e
Cough 30 90 22 (24%) 0 (0%) 362 171 (47%) 9 (2%) ,0.0001 0.22e
Ear/nose/throat inflammation 31 90 13 (14%) 0 (0%) 362 120 (33%) 20 (6%) 0.0005 0.0188e
Erectile function/ability to make love 32 90 10 (11%) 2 (2%) 362 71 (20%) 34 (9%) 0.06 0.0246
Nausea, vomiting 33 90 20 (22%) 0 (0%) 363 179 (49%) 12 (3%) ,0.0001 0.14e
Diarrhea 34 90 6 (7%) 0 (0%) 363 127 (35%) 10 (3%) ,0.0001 0.22e
Warts 35 90 14 (16%) 1 (1%) 363 82 (23%) 10 (3%) 0.14 0.70e
Pain 36 90 4 (4%) 0 (0%) 362 71 (20%) 7 (2%) 0.0005 0.35e
Folliculitis 37 90 7 (8%) 1 (1%) 362 56 (15%) 6 (2%) 0.06 1.00e
Dysuria 38 90 6 (7%) 0 (0%) 362 51 (14%) 3 (1%) 0.06 1.00e
aSymptoms were ranked according to the average score (grade6weight).
bP-values were calculated between controls and patients by Chi square test except where noted.
cGrades 1–4.
dGrades 3 and 4 only.
eP-value calculated by Fisher’s exact test. Statistically significant differences (,0.05) are shown in italics.
doi:10.1371/journal.pone.0002266.t003
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Discussion
This study was the first large-scale, comprehensive analysis of
perceived disability in mastocytosis patients. The study included
363 mastocytosis patients in France identified by the AFIRMM
network along with 90 control participants. The patient cohort
included a mixture of patients with CM and indolent and
aggressive forms of SM but no patients with mast cell leukemia.
According to the OPA score, which was a unidimensional self-
assessment of disability, a majority of mastocytosis patients (70%)
Table 4. Disability by symptom: comparison by classification (CM vs. SM).
Symptom CM SM P-value
a
n Any disabilityb
Severe or
intolerable
disabilityc n
Any
disabilityb
Severe or
intolerable
disabilityc
Any
disabilityb
Severe or
intolerable
disabilityc
Psychological impact 33 27 (82%) 12 (36%) 82 61 (74%) 33 (40%) 0.40 0.70
Asthenia 33 25 (76%) 9 (27%) 81 68 (84%) 29 (36%) 0.31 0.38
Pruritus 33 26 (79%) 6 (18%) 82 69 (84%) 23 (28%) 0.49 0.27
Food allergy/intolerance 33 19 (58%) 7 (21%) 82 52 (63%) 19 (23%) 0.56 0.82
Erythemateous crisis 33 26 (79%) 6 (18%) 82 70 (85%) 20 (24%) 0.39 0.47
Muscle and joint pain, cramps 33 23 (70%) 7 (21%) 82 72 (88%) 23 (28%) 0.0205 0.45
Pollakiuria 33 21 (64%) 5 (15%) 81 60 (74%) 20 (25%) 0.27 0.26
Drug allergy 33 19 (58%) 3 (9%) 82 48 (59%) 17 (21%) 0.92 0.14
Aerophagia/eructation 33 19 (58%) 6 (18%) 82 52 (63%) 13 (16%) 0.56 0.76
Dyspnea/bronchoreactivity 33 14 (42%) 8 (24%) 81 37 (46%) 24 (30%) 0.75 0.56
Headache 33 24 (73%) 5 (15%) 81 58 (72%) 9 (11%) 0.90 0.54d
Bone pain 33 18 (55%) 7 (21%) 82 58 (71%) 17 (21%) 0.10 0.95
Reduced sexual relations 33 7 (21%) 3 (9%) 82 41 (50%) 20 (24%) 0.0046 0.06
Epigastric pain 33 22 (67%) 2 (6%) 82 50 (61%) 8 (10%) 0.57 0.72d
Ocular discomfort 33 20 (61%) 5 (15%) 82 47 (57%) 10 (12%) 0.75 0.76d
Memory loss 33 21 (64%) 1 (3%) 81 58 (72%) 15 (19%) 0.40 0.0366d
Tinnitus 33 16 (48%) 5 (15%) 82 39 (48%) 15 (18%) 0.93 0.69
Pseudo-occlusive syndrome 33 11 (33%) 1 (3%) 82 47 (57%) 9 (11%) 0.0200 0.28d
Infections (bronchitis, rhinitis, conjunctivitis) 33 14 (42%) 2 (6%) 82 42 (51%) 10 (12%) 0.39 0.50d
Olfactive intolerance 33 17 (52%) 1 (3%) 82 48 (59%) 8 (10%) 0.49 0.44d
Social interaction 33 14 (42%) 1 (3%) 81 46 (57%) 7 (9%) 0.16 0.43d
Depression 33 15 (45%) 3 (9%) 81 51 (63%) 6 (7%) 0.09 0.72d
Mobility 33 14 (42%) 2 (6%) 82 47 (57%) 13 (16%) 0.15 0.23d
Anaphylactic shock 33 16 (48%) 3 (9%) 82 39 (48%) 8 (10%) 0.93 1.00d
Sweat 33 17 (52%) 3 (9%) 82 34 (41%) 8 (10%) 0.33 1.00d
Stomatitis 33 11 (33%) 3 (9%) 82 33 (40%) 10 (12%) 0.49 0.75d
Flush 33 23 (70%) 2 (6%) 82 47 (57%) 7 (9%) 0.22 1.00d
Performance status 33 16 (48%) 3 (9%) 81 53 (65%) 11 (14%) 0.09 0.75d
Hemorrhoids 33 10 (30%) 1 (3%) 82 40 (49%) 10 (12%) 0.07 0.17d
Cough 33 15 (45%) 0 (0%) 81 43 (53%) 2 (2%) 0.46 1.00d
Ear/nose/throat inflammation 33 11 (33%) 1 (3%) 81 24 (30%) 5 (6%) 0.70 0.67d
Erectile function/ability to make love 33 1 (3%) 0 (0%) 81 25 (31%) 12 (15%) 0.0013 0.0176
Nausea, vomiting 33 15 (45%) 2 (6%) 82 48 (59%) 3 (4%) 0.20 0.62d
Diarrhea 33 11 (33%) 0 (0%) 82 29 (35%) 6 (7%) 0.84 0.18d
Warts 33 6 (18%) 0 (0%) 82 16 (20%) 4 (5%) 0.87 0.32d
Pain 33 5 (15%) 0 (0%) 81 17 (21%) 3 (4%) 0.47 0.56d
Folliculitis 33 5 (15%) 1 (3%) 81 10 (12%) 1 (1%) 0.76 0.50d
Dysuria 33 4 (12%) 0 (0%) 81 15 (19%) 1 (1%) 0.41 1.00d
aP-values were calculated between CM and SM by Chi square test except where noted.
bGrades 1–4.
cGrades 3 and 4 only.
dP-value calculated by Fisher’s exact test. Symptoms are listed in the same order as in Table 4. Statistically significant differences (,0.05) are shown in italics.
doi:10.1371/journal.pone.0002266.t004
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feel that they suffer from a disability, whereas only a minority of
the controls (9%) indicated having a disability. We further
examined patients’ self-reported disability using the AFIRMM
questionnaire and score, which were designed to provide a more
comprehensive analysis of perceived disabilities from mastocytosis.
The AFIRMM scores confirmed that most mastocytosis patients
feel disabled by their disease symptoms. This perception of
disability corresponded with the finding that a majority of
mastocytosis patients had at least one of the seven measurable
disabilities including life-threatening anaphylactoid episodes, 7 or
Table 5. Disability by symptom: comparison by the presence or absence of D816V KIT mutation.
Symptom No D816V D816V P-value
a
n
Any
disabilityb
Severe or
intolerable
disabilityc n
Any
disabilityb
Severe or
intolerable
disabilityc
Any
disabilityb
Severe or
intolerable
disabilityc
Psychological impact 72 41 (57%) 18 (25%) 162 133 (82%) 71 (44%) ,0.0001 0.0062
Asthenia 72 62 (86%) 26 (36%) 161 133 (83%) 45 (28%) 0.50 0.21
Pruritus 72 64 (89%) 18 (25%) 162 132 (81%) 42 (26%) 0.16 0.88
Food allergy/intolerance 72 46 (64%) 17 (24%) 162 95 (59%) 42 (26%) 0.45 0.71
Erythemateous crisis 72 52 (72%) 11 (15%) 162 140 (86%) 35 (22%) 0.0090 0.26
Muscle and joint pain, cramps 72 55 (76%) 21 (29%) 162 127 (78%) 28 (17%) 0.73 0.0392
Pollakiuria 72 47 (65%) 13 (18%) 161 120 (75%) 32 (20%) 0.15 0.75
Drug allergy 72 43 (60%) 15 (21%) 162 92 (57%) 31 (19%) 0.68 0.76
Aerophagia/eructation 72 50 (69%) 16 (22%) 162 94 (58%) 29 (18%) 0.10 0.44
Dyspnea/bronchoreactivity 72 34 (47%) 23 (32%) 161 68 (42%) 44 (27%) 0.48 0.47
Headache 72 53 (74%) 11 (15%) 161 108 (67%) 21 (13%) 0.32 0.65
Bone pain 72 41 (57%) 14 (19%) 162 90 (56%) 27 (17%) 0.84 0.61
Reduced sexual relations 72 29 (40%) 16 (22%) 161 62 (39%) 31 (19%) 0.80 0.60
Epigastric pain 72 53 (74%) 12 (17%) 162 97 (60%) 15 (9%) 0.0432 0.10
Ocular discomfort 72 52 (72%) 12 (17%) 162 89 (55%) 27 (17%) 0.0126 1.00
Memory loss 72 47 (65%) 6 (8%) 161 107 (66%) 19 (12%) 0.86 0.43
Tinnitus 72 33 (46%) 9 (13%) 162 80 (49%) 22 (14%) 0.62 0.82
Pseudo-occlusive syndrome 72 32 (44%) 7 (10%) 162 95 (59%) 16 (10%) 0.0442 0.97
Infections (bronchitis, rhinitis, conjunctivitis) 72 39 (54%) 8 (11%) 162 75 (46%) 18 (11%) 0.27 1.00
Olfactive intolerance 72 45 (63%) 10 (14%) 162 75 (46%) 12 (7%) 0.0221 0.12
Social interaction 72 41 (57%) 8 (11%) 161 87 (54%) 11 (7%) 0.68 0.27
Depression 72 41 (57%) 6 (8%) 161 99 (61%) 14 (9%) 0.51 0.93
Mobility 72 40 (56%) 9 (13%) 162 67 (41%) 15 (9%) 0.0442 0.45
Anaphylactic shock 72 40 (56%) 7 (10%) 162 72 (44%) 14 (9%) 0.12 0.79
Sweat 72 39 (54%) 10 (14%) 162 74 (46%) 13 (8%) 0.23 0.16
Stomatitis 72 36 (50%) 10 (14%) 162 58 (36%) 13 (8%) 0.0409 0.16
Flush 72 41 (57%) 4 (6%) 162 97 (60%) 11 (7%) 0.67 1.00d
Performance status 72 44 (61%) 6 (8%) 161 83 (52%) 13 (8%) 0.18 0.95
Hemorrhoids 72 31 (43%) 5 (7%) 162 76 (47%) 12 (7%) 0.58 0.90
Cough 72 40 (56%) 2 (3%) 161 68 (42%) 6 (4%) 0.06 1.00d
Ear/nose/throat inflammation 72 26 (36%) 5 (7%) 161 53 (33%) 6 (4%) 0.63 0.32d
Erectile function/ability to make love 72 16 (22%) 7 (10%) 161 34 (21%) 16 (10%) 0.85 0.96
Nausea, vomiting 72 43 (60%) 4 (6%) 162 79 (49%) 7 (4%) 0.12 0.74d
Diarrhea 72 33 (46%) 2 (3%) 162 53 (33%) 5 (3%) 0.05 1.00d
Warts 72 19 (26%) 2 (3%) 162 31 (19%) 5 (3%) 0.21 1.00d
Pain 72 17 (24%) 2 (3%) 161 28 (17%) 3 (2%) 0.27 0.65d
Folliculitis 72 12 (17%) 1 (1%) 161 22 (14%) 3 (2%) 0.55 1.00d
Dysuria 72 9 (13%) 1 (1%) 161 22 (14%) 0 (0%) 0.81 0.31d
aP-value calculated between CM and SM by Chi square test except where noted.
bGrades 1–4.
cGrades 3 and 4 only.
dP-value calculated by Fisher’s exact test. Symptoms are listed in the same order as in Table 4. Statistically significant differences (,0.05) are shown in italics.
doi:10.1371/journal.pone.0002266.t005
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more episodes of flushing per week, 4 or more stools per day
(diarrhea), 8 or more micturitions per day (pollakiuria), a pruritus
score of 6 or more, a Hamilton rating score of 10 or more
(depression), or a QLQ-C30 score of 60 or more.
Analysis of the severity for the 38 individual symptoms on the
AFIRMM questionnaire suggested that mastocytosis patients
suffer from a wide variety of symptoms: for at least 32 of the 38
symptoms, there was a significant difference between the number
Table 6. Disability by symptom: comparison by serum tryptase level.
Symptom #20 ng/ml .20 ng/ml P-value
a
n
Any
disabilityb
Severe or
intolerable
disabilityc n
Any
disabilityb
Severe or
intolerable
disabilityc
Any
disabilityb
Severe or
intolerable
disabilityc
Psychological impact 53 34 (64%) 13 (25%) 87 67 (77%) 41 (47%) 0.10 0.0077
Asthenia 53 46 (87%) 20 (38%) 86 67 (78%) 27 (31%) 0.19 0.44
Pruritus 53 42 (79%) 13 (25%) 87 71 (82%) 19 (22%) 0.73 0.71
Food allergy/intolerance 53 32 (60%) 12 (23%) 87 52 (60%) 18 (21%) 0.94 0.78
Erythemateous crisis 53 40 (75%) 8 (15%) 87 71 (82%) 20 (23%) 0.38 0.26
Muscle and joint pain, cramps 53 41 (77%) 13 (25%) 87 68 (78%) 19 (22%) 0.91 0.71
Pollakiuria 53 35 (66%) 10 (19%) 86 60 (70%) 17 (20%) 0.65 0.90
Drug allergy 53 33 (62%) 9 (17%) 87 47 (54%) 19 (22%) 0.34 0.49
Aerophagia/eructation 53 30 (57%) 4 (8%) 87 51 (59%) 16 (18%) 0.81 0.08
Dyspnea/bronchoreactivity 53 23 (43%) 16 (30%) 86 38 (44%) 27 (31%) 0.93 0.88
Headache 53 35 (66%) 7 (13%) 86 58 (67%) 8 (9%) 0.86 0.47
Bone pain 53 31 (58%) 10 (19%) 87 56 (64%) 19 (22%) 0.49 0.67
Reduced sexual relations 53 20 (38%) 7 (13%) 87 35 (40%) 20 (23%) 0.77 0.15
Epigastric pain 53 31 (58%) 2 (4%) 87 54 (62%) 11 (13%) 0.67 0.13d
Ocular discomfort 53 37 (70%) 8 (15%) 87 42 (48%) 11 (13%) 0.0127 0.68
Memory loss 53 36 (68%) 6 (11%) 86 58 (67%) 7 (8%) 0.95 0.56d
Tinnitus 53 28 (53%) 9 (17%) 87 38 (44%) 12 (14%) 0.29 0.61
Pseudo-occlusive syndrome 53 23 (43%) 4 (8%) 87 48 (55%) 7 (8%) 0.18 1.00d
Infections (bronchitis, rhinitis, conjunctivitis) 53 26 (49%) 4 (8%) 87 38 (44%) 9 (10%) 0.54 0.77d
Olfactive intolerance 53 33 (62%) 10 (19%) 87 41 (47%) 3 (3%) 0.08 0.0047d
Social interaction 53 28 (53%) 3 (6%) 86 41 (48%) 6 (7%) 0.55 1.00d
Depression 53 33 (62%) 4 (8%) 86 48 (56%) 6 (7%) 0.45 1.00d
Mobility 53 25 (47%) 5 (9%) 87 45 (52%) 12 (14%) 0.60 0.44
Anaphylactic shock 53 26 (49%) 5 (9%) 87 41 (47%) 6 (7%) 0.82 0.75d
Sweat 53 28 (53%) 5 (9%) 87 38 (44%) 8 (9%) 0.29 1.00d
Stomatitis 53 23 (43%) 7 (13%) 87 28 (32%) 9 (10%) 0.18 0.61
Flush 53 31 (58%) 6 (11%) 87 45 (52%) 6 (7%) 0.44 0.37d
Performance status 53 33 (62%) 2 (4%) 86 49 (57%) 10 (12%) 0.54 0.13d
Hemorrhoids 53 19 (36%) 2 (4%) 87 43 (49%) 9 (10%) 0.12 0.21d
Cough 53 27 (51%) 1 (2%) 86 39 (45%) 1 (1%) 0.52 1.00d
Ear/nose/throat inflammation 53 14 (26%) 3 (6%) 86 25 (29%) 4 (5%) 0.74 1.00d
Erectile function/ability to make love 53 5 (9%) 1 (2%) 86 19 (22%) 10 (12%) 0.06 0.05d
Nausea, vomiting 53 33 (62%) 3 (6%) 87 40 (46%) 2 (2%) 0.06 0.37d
Diarrhea 53 18 (34%) 2 (4%) 87 29 (33%) 4 (5%) 0.94 1.00d
Warts 53 13 (25%) 1 (2%) 87 15 (17%) 3 (3%) 0.30 1.00d
Pain 53 11 (21%) 0 (0%) 86 17 (20%) 1 (1%) 0.89 1.00d
Folliculitis 53 5 (9%) 0 (0%) 86 15 (17%) 3 (3%) 0.19 0.29d
Dysuria 53 8 (15%) 0 (0%) 86 10 (12%) 1 (1%) 0.55 1.00d
aP-value calculated between CM and SM by Chi square test except where noted.
bGrades 1–4.
cGrades 3 and 4 only.
dP-value calculated by Fisher’s exact test. Symptoms are listed in the same order as in Table 4. Statistically significant differences (,0.05) are shown in italics.
doi:10.1371/journal.pone.0002266.t006
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of patients and controls reporting a disability. Analysis of the
scores (Grade6Weight) for each symptom revealed that the 10
symptoms that most contributed to the perception of disability
were (in decreasing order) psychological impact, asthenia, pruritus,
food allergy/intolerance, erythemateous crisis, muscle and joint
pain/cramps, pollakiuria, drug allergy, aerophagia/eruction, and
dyspnea/bronchoreactivity. Our results also confirmed the
existence of number of previously described symptoms associated
with mastocytosis, including fatigue (asthenia), anaphylaxis,
sweating, flushing, pruritus, erythemateous crises, epigastric pain,
diarrhea, nausea/vomiting, bone pain, headache, memory loss,
difficulty with social interactions, reduced performance status, and
depression [3,17]. Importantly, our results reveal that the number
of symptoms significantly associated with mastocytosis appears to
be even larger than previously considered; for the first time, we
provide strong evidence that mastocytosis patients also feel
disabled by food and drug allergy/intolerance, muscle/joint pain
and cramps, aerophagia/eruction, reduced sexual relations, ocular
discomfort, tinnitus, pseudo-occlusive syndrome, infections (bron-
chitis, rhinitis, and conjunctivitis), olfactive intolerance, reduced
mobility, hemorrhoidal inflammation, cough, ear/nose/throat
inflammation, and general pain (Table 11).
An important finding from this analysis was that psychological
and neurological symptoms appear to be key contributors to
disability in mastocytosis. We found that the psychological impact
of the skin appearance was the symptom that most contributed to
perception of disability in all mastocytosis patients: 72% of patients
reported some disability due to this symptom, and 23% considered
it severe or intolerable. Asthenia was another very common
complaint, with 82% of mastocytosis patients reporting a
disability, and a high proportion (28%) describing it as severe or
intolerable. Also, patients reported suffering from reduced
performance status (52%), difficulty with social interactions
(55%), depression (57%), memory loss (66%), headache (69%),
and pain (20%). That depression is a common symptom of
mastocytosis was confirmed by the finding that more than 70% of
all mastocytosis patients had a Hamilton score .10. Our
observation that psychological and neurological effects are
common in mastocytosis extends earlier findings by Rogers et al.
[17], who found that SM is associated with diminished attention
and memory, anger, irritability, and depression, a combination of
symptoms that they referred to as an ‘‘atypical or mixed organic
brain syndrome’’. Also, a study in the late 1970s by Soter et al.
[18] reported neuropsychiatric symptoms in five of eight
mastocytosis patients, including poor attention span, irritability,
fatigue, difficulty in concentrating, headache, inability to work
effectively, problems in dealing with other people, and poor
motivation. Overall, our results support the notion that the
neurologic manifestations of SM are more common than
previously thought [19], and they support the suggestion that
mastocytosis patients may often be misdiagnosed due the
nonspecificity of their neurologic symptoms [3].
In addition, our findings confirm that cutaneous, gastrointesti-
nal, and skeletal symptoms are common to SM [3,20]. We also
found that pulmonary symptoms (i.e., cough and dyspnea/
bronchoreactivity) are significantly associated with mastocytosis.
In fact, 26% of all mastocytosis patients report suffering from
severe or intolerable dyspnea or bronchoreactivity, and this
symptom was the tenth most important contributor to overall
disability according to the AFIRMM score. Another unexpected
finding was that reduced sexual relations was one of the more
important symptoms, with as many as 18% of patients describing
it as severe or intolerable.
The key finding of this study was that the overall extent of
disability and the type and severity symptoms were essentially the
same between CM and SM patients. Initially, we found that
patients’ overall perception of disability as determined by both the
OPA and AFIRMM scores does not depend on the clinical form of
the disease. Importantly, we also found that there was no statistical
difference between CM and SM in the seven standard measures of
disability. These unexpected findings were confirmed when the
analyses were limited to patients whose diagnosis of mastocytosis
was validated by a careful centralized review of pathological and
clinical data. On the basis of these results, we propose that CM
Table 7. Standard measures of disability.
Parameter n
No. with
handicap
Existence of recurrent life-threatening
anaphylactoid episodes
153 29 (19%)
$7 flushes per week 92 61 (66%)
$4 stools per day 90 11 (12%)
$8 micturitions per day 92 29 (32%)
Pruritus score $6 90 69 (77%)
Hamilton scale $10 88 66 (75%)
QLQ-C30 $60 124 40 (32%)
Data was collected from the 262 patients that participated in the
pathophysiological study.
doi:10.1371/journal.pone.0002266.t007
Table 8. Standard measures of disability: comparison by classification.
Parameter CM SM P-valuea
n No. with handicap n No. with handicap
Existence of recurrent life-threatening anaphylactoid episodes 21 3 (14%) 61 10 (16%) 1.00
$7 flushes per week 8 6 (75%) 28 19 (68%) 1.00
$4 stools per day 7 2 (29%) 28 4 (14%) 1.00
$8 micturitions per day 8 1 (13%) 28 8 (29%) 1.00
Pruritus score $6 8 7 (88%) 27 19 (70%) 1.00
Hamilton scale $10 8 7 (88%) 26 22 (85%) 1.00
QLQ-C30 $60 10 4 (40%) 34 14 (41%) 1.00
aP-value calculated by Fisher’s exact test. Data was collected from the 262 patients that participated in the pathophysiological study.
doi:10.1371/journal.pone.0002266.t008
Disability in Mastocytosis
PLoS ONE | www.plosone.org 11 May 2008 | Volume 3 | Issue 5 | e2266
Table 10. Standard measures of disability: comparison by serum tryptase level.
Parameter #20 ng/ml .20 ng/ml P-value
n No. with handicap n No. with handicap
Existence of recurrent life-threatening anaphylactoid
episodes
28 4 (14%) 63 9 (14%) 1.00b
$7 flushes per week 15 12 (80%) 29 17 (59%) 0.16a
$4 stools per day 15 2 (13%) 28 4 (14%) 0.27b
$8 micturitions per day 15 5 (33%) 29 5 (17%) 0.74b
Pruritus score $6 14 10 (71%) 28 18 (64%) 0.45b
Hamilton scale $10 14 12 (86%) 27 19 (70%) 0.38a
QLQ-C30 $60 24 10 (42%) 36 11 (31%) 0.82a
aP-value calculated by Chi-square test.
bP-value calculated by Fisher’s exact test. Data was collected from the 262 patients that participated in the pathophysiological study.
doi:10.1371/journal.pone.0002266.t010
Table 11. Symptoms significantly associated with mastocytosis according to AFIRMM score.
Previously identified symptomsa Symptoms not previously reported
Fatigue (asthenia) Food and drug allergy/intolerance
Anaphylaxis Muscle/joint pain and cramps
Sweating Aerophagia/eruction
Flushing Reduced sexual relations
Pruritus Ocular discomfort
Erythemateous crises Tinnitus
Epigastric pain Pseudo-occlusive syndrome
Diarrhea Infections (bronchitis, rhinitis, and conjunctivitis)
Dyspnea/bronchoreactivity Olfactive intolerance
Nausea/vomiting Reduced mobility
Bone pain Hemorrhoidal inflammation
Headache Cough
Memory loss Ear/nose/throat inflammation
Difficulty with social interactions General pain
Reduced performance status
Depression
aSymptoms previously identified as described in references 3, 17, 20.
doi:10.1371/journal.pone.0002266.t011
Table 9. Standard measures of disability: comparison by KIT mutation status.
Parameter No D816V D816V P-value
n No. with handicap n No. with handicap
Existence of recurrent life-threatening anaphylactoid episodes 37 8 (22%) 102 16 (16%) 0.41a
$7 flushes per week 18 13 (72%) 67 45 (67%) 0.68a
$4 stools per day 18 2 (11%) 65 8 (12%) 1.00b
$8 micturitions per day 18 5 (28%) 67 21 (31%) 0.77a
Pruritus score $6 18 13 (72%) 66 51 (77%) 0.76b
Hamilton scale $10 18 14 (78%) 63 48 (76%) 1.00b
QLQ-C30 $60 28 9 (32%) 82 23 (28%) 0.68a
aP-value calculated by Chi-square test.
bP-value calculated by Fisher’s exact test.
doi:10.1371/journal.pone.0002266.t009
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and SM and their different subtypes are not distinct diseases but
are part of a continuous spectrum of mast cell-related dysfunctions.
Furthermore, this implies that the presence of excessive mast cells
in extracutaneous tissues such as bone marrow is not helpful for
understanding the disability and symptoms–real and/or per-
ceived–of mastocytosis patients.
The KIT D816V mutation has been suggested to correlate with
the occurrence of SM in adult patients and to contribute to its
progression [1,13]. However, there was no difference in disability
as measured by OPA score, AFIRMM score, or measurable
parameters of disability between patients with and without this
mutation. Likewise, for 37 of the 38 symptoms, there was little or
no difference in the fraction of patients reporting a disability
according to the presence of the D816V mutation. Thus, the type
and severity of mastocytosis symptoms appears to be unrelated to
the presence of the D816V KIT mutation.
We also did not find a significant difference in the overall
perception of disability (OPA and AFIRMM scores) or standard
measures of disability according to the serum tryptase level (#20
vs. .20 ng/mL). Likewise, the serum tryptase level appeared to
have no bearing on the severity of the 38 individual symptoms as
measured by the AFIRMM score or the standard measures.
Because our assay measured total tryptase levels, which is an
indicator of total mast cell burden [14], it appears that the type
and severity of most symptoms are unrelated to elevated mast cell
numbers. Accordingly, we expect that the level of activated,
mature tryptase, which is a measure of mast cell activation [14],
will be more useful than total serum tryptase for understanding the
pathogenesis of mastocytosis.
Conclusions
In summary, these results suggest that the existing classification
system for mastocytosis does not help understand patients’ overall
perception of disability, their individual symptoms, or their impact
on the quality of life. It appears that the presence of elevated mast
cell numbers in bone marrow or extracutaneous tissues, an
elevated serum tryptase level, and the D816V KIT mutation has
little or no bearing on the type or severity symptoms. Given these
results, we suspect that the symptoms of indolent mastocytosis are
mostly unrelated to mast cell proliferation or infiltration; rather, it
appears that the symptoms are the result of mast cell activation
and the systemic release of mediators. On this basis, we propose an
alternative classification system to help in the treatment of
mastocytosis patients, namely, that (i) mast cell leukemia and
aggressive mastocytosis be considered and treated separately from
indolent forms and (ii) that indolent mastocytosis be classified and
treated simply according to the patient’s perception of disability
due to symptoms of the disease.
Another important finding was that, although none of the
symptoms are specific to the disease, the number associated with
mastocytosis is even higher than previously realized and includes
some symptoms that have been largely overlooked, especially
neuropsychiatric symptoms. Given the wide variety and non-
specificity of these symptoms, we suspect that many mastocytosis
patients are misdiagnosed and that the prevalence of mastocytosis
is therefore higher than previously considered.
Finally, as part of the current study, we developed and validated
a questionnaire and composite score for assessing patients’
perception of disability in mastocytosis (AFIRMM score). This
scoring system should be useful in evaluating the efficacy of
mastocytosis treatments in future clinical trials and for further
understanding the nature of symptoms and disability from
mastocytosis.
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